Advent Life Sciences

Advent Life Sciences portfolio company AviadoBio has signed an exclusive option and licence agreement for AVB-101, a clinical stage gene therapy targeting Frontotemporal Dementia (FTD) and other indications. This collaboration holds tremendous promise in addressing the significant unmet needs in neurodegenerative diseases like FTD, which deeply affect patients and their families. We believe this partnership will accelerate the development of this much-needed therapy and highlight the potential of cutting-edge gene therapies. Congratulations to the teams at AviadoBio and Astellas Gene Therapies on reaching this important milestone! For more information please visit: https://lnkd.in/e3CrzXPN  #GeneTherapy #HealthcareInnovation #FTD

We are excited to share that Amphista Therapeutics Limited, one of our biotech portfolio companies founded by Advent Life Sciences, has appointed Antony Mattessich as the new CEO! Antony brings a wealth of experience to the exceptional leadership team of Amphista and a passion for advancing therapeutics towards generating real impact for patients. Please join us in welcoming Antony to the team! Read the full announcement here: https://lnkd.in/eMrtrkuf #biotech #tpd #targetedglue #proteindegradation #vc

Advent Life Sciences is thrilled to join Beacon Therapeutics in their journey to becoming a leading retinal gene therapy company. We are proud to announce our participation in the $170 million Series B funding round, alongside Forbion, Syncona Limited , TCGX and Oxford Science Enterprises. This funding will accelerate the development of Beacon’s lead asset, AGTC-501, for X-Linked Retinitis Pigmentosa (XLRP) and advance their promising pipeline. We are committed to supporting ground-breaking innovations that aim to save and restore vision for patients with blinding retinal diseases. Congratulations to David Fellows and the entire Beacon team on this significant milestone! We look forward to seeing the impactful advancements that will emerge from Beacon Therapeutics. See the press release below for more information. #LifeSciences #GeneTherapy #Ophthalmology #Investment #Innovation #BeaconTherapeutics https://lnkd.in/e7Tf4PwP

We're thrilled to share a major milestone achieved by one of our portfolio companies, AviadoBio! 🚀 The first patient has been treated in the Phase 1/2 ASPIRE-FTD trial, evaluating AVB-101 for frontotemporal dementia (FTD) with progranulin (GRN) gene mutations. This marks a significant step forward in intrathalamic gene therapy delivery for adult neurodegenerative diseases. At Advent Life Sciences, we're passionate about supporting groundbreaking innovations in healthcare, and AviadoBio's progress is a testament to that commitment. We believe in the potential of AVB-101 to transform the lives of individuals affected by FTD-GRN and commend the dedication of the entire AviadoBio team. Congratulations to AviadoBio on this achievement, and we look forward to continuing to support their journey towards pioneering treatments for neurodegenerative disorders! 🧬 #HealthcareInnovation #Neurotherapeutics #VC #MilestoneAchievement https://lnkd.in/eVteGaRQ

Argá Medtech SA secures €54M Series B funding, led by Advent Life Sciences, Earlybird Venture Capital, Gilde Healthcare and an undisclosed strategic investor. The funding is going to advance Coherent Sine-Burst Electroporation™ (CSE™) Pulsed Field Ablation system for treating atrial fibrillation. Argá Medtech’s CSE™ ablation system enables electrophysiologists to treat any region in the heart safely and efficiently using a single, multi-configurable catheter while titrating lesion depths according to the location within the heart. Heartfelt congratulations to the entire Argá Medtech SA team for their dedication and hard work in securing this significant capital raise. Together, we are poised to make meaningful strides in transforming cardiac care and improving the lives of patients worldwide. https://lnkd.in/ebZ_mU-b #ArgáMedtech #SeriesB #CardiacAblation #Innovation #MedicalTechnology

Thrilled to announce a major milestone for Advent Life Sciences founded portfolio company, Curve Therapeutics! 🚀 We're delighted to share that Curve Therapeutics has successfully raised a substantial £40.5m in its Series A funding round. This significant investment will be pivotal in propelling forward its groundbreaking Microcycle platform and advancing pipeline assets aimed at tackling some of the most difficult cancer targets. Massive congratulations are in order to Simon Kerry, Ali Tavassoli, and the entire dedicated team at Curve Therapeutics! #AdventLifeSciences #CurveTherapeutics #SeriesA #CancerResearch #Innovation #Biotech #Investment #Milestone #TeamEffort https://lnkd.in/eeXsfgbX

Thrilled to share exciting updates from Amphista Therapeutics Limited, founded by Advent Life Sciences. Recent data highlight significant progress in the in vivo efficacy and CNS activity of their innovative targeted protein degraders. Particularly noteworthy is Amphista's success in achieving efficacy in disease-relevant models through orally delivered non-cereblon/non-VHL-based protein degraders as well as the CNS activity achieved. Applauding the Amphista team for the impressive progress. #biotech #innovation #lifesciences #cns #drugdiscovery https://lnkd.in/eYFdnv-u

We are excited to announce that Eliot Forster has joined LEVICEPT LTD as CEO, bringing more than thirty years of biotech experience to the company. Welcome Eliot, and we look forward to working with you! Please find a link to the full press release below: https://lnkd.in/ej9vhByp

Congratulations to Advent Life Sciences' portfolio company Artax Biopharma Inc., a clinical-stage biotechnology company focused on transforming the treatment of T Cell-mediated diseases, which announced that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted clinical trial authorization (CTA) to evaluate AX-158 in a Phase 2a psoriasis study. Please find a link to the full press release below: https://lnkd.in/exjxxQz2 #biotechnology #biotech #psoriasis #venturecapital

We are pleased to share a significant achievement within our portfolio as AviadoBio Investigational New Drug (IND) application for AVB-101, designed for individuals with frontotemporal dementia (FTD) carrying mutations in the progranulin (GRN) gene, has received clearance from the U.S. Food and Drug Administration (FDA). Furthermore, we are delighted to share that the FDA has granted Fast Track designation to AVB-101. These milestones mark pivotal moments on our path to developing a groundbreaking therapy for this devastating form of early-onset dementia.   For more details, please refer to the official press release linked below:   https://lnkd.in/eQhuKGJk   #VentureCapital #HealthcareInnovation #ClinicalTrial #PortfolioCompany #HealthTech #Innovation #FTD #Dementia #AAV #FDA #IND